Verity Patent-Cliff Exposure & CMS Drug Spending Portfolio
Verity (US): 2 reconciled FDA prescription therapies (95.0% 2025 to 2030 cliff risk), $17.6M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 2 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 95.0% |
| Primary Portfolio LOE Date | 2029-01-01 |
| 2024 CMS Total Public Spend | $17.6M |
| 2024 Medicare Part D Spend | $16.0M |
| 2024 Medicaid Spend | $1.6M |
| California HCAI SB 17 Filings | 5 WAC filings (max 29.2% 2-yr change) |